Publications by authors named "Paul Delaunay"
Article Synopsis
- The study aimed to gather real-life data on how ibrutinib is used and its safety profiles in patients between November 2014 and November 2018.
- A total of 102 patients participated, mainly receiving ibrutinib for chronic lymphocytic leukemia (CLL), with 47.1% experiencing serious adverse drug reactions (SADRs) within the first year.
- The findings highlighted that older patients (aged ≥80) and those with CLL had a higher risk of developing SADRs, indicating that they require closer monitoring during treatment.
Hearing loss is defined as a decrease in the ability to perceive sounds which can occur suddenly or gradually and affects one ear or both. It is related to various etiologies, in particular drugs. The identification of all drugs that could be associated with hearing loss is essential for the patients' life quality.
View Article and Find Full Text PDF